Research
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6423 (Published 25 October 2011) Cite this as: BMJ 2011;343:d6423Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - International classification of diseases codes used in study
- Data Supplement - Codes for excluded diagnoses
- Data Supplement - Appendix 1: allocation rules applied in analysis
- Data Supplement - Appendix 2: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; different exposure line formation
- Data Supplement - Appendix 3: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; three sub-periods and during 2001-9
- Data Supplement - Appendix 4: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; different user categories during 2001-9
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - International classification of diseases codes used in study
- Data Supplement - Codes for excluded diagnoses
- Data Supplement - Appendix 1: allocation rules applied in analysis
- Data Supplement - Appendix 2: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; different exposure line formation
- Data Supplement - Appendix 3: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; three sub-periods and during 2001-9
- Data Supplement - Appendix 4: rate ratios of venous thromboembolism with use of oral contraceptives with 3-40 ���g ethinylestradiol; different user categories during 2001-9
Related articles
- Paper Published: 13 January 1996; BMJ 312 doi:10.1136/bmj.312.7023.83
- Research Published: 13 August 2009; BMJ 339 doi:10.1136/bmj.b2890
- Editorial Published: 25 October 2011; BMJ 343 doi:10.1136/bmj.d6592
- Research Published: 13 August 2009; BMJ 339 doi:10.1136/bmj.b2921
- Fillers Published: 11 November 2000; BMJ 321 doi:10.1136/bmj.321.7270.1190
- News Published: 10 January 2012; BMJ 344 doi:10.1136/bmj.e244
- Research Published: 10 May 2012; BMJ 344 doi:10.1136/bmj.e2990
- Research Published: 07 August 2012; BMJ 345 doi:10.1136/bmj.e4944
- Research Published: 30 November 2012; BMJ 345 doi:10.1136/bmj.e7885
- Research Published: 12 September 2013; BMJ 347 doi:10.1136/bmj.f5298
- Research Published: 26 May 2015; BMJ 350 doi:10.1136/bmj.h2135
- Editorial Published: 26 May 2015; BMJ 350 doi:10.1136/bmj.h2422
- Research Published: 10 May 2016; BMJ 353 doi:10.1136/bmj.i2002
- Practice Published: 08 October 2015; BMJ 351 doi:10.1136/bmj.h4847
- Editorial Published: 10 May 2016; BMJ 353 doi:10.1136/bmj.i2544
- Research Published: 30 November 2016; BMJ 355 doi:10.1136/bmj.i5968
- Research Published: 06 September 2023; BMJ 382 doi:10.1136/bmj-2022-074450
See more
- Scandal of “newborn gang” that put profits ahead of babies’ lives rocks Turkey’s health systemBMJ November 07, 2024, 387 q2466; DOI: https://doi.org/10.1136/bmj.q2466
- NICE reiterates importance of HRT for menopausal symptomsBMJ November 07, 2024, 387 q2460; DOI: https://doi.org/10.1136/bmj.q2460
- The commercial determinants of infant and child healthBMJ October 31, 2024, 387 q2395; DOI: https://doi.org/10.1136/bmj.q2395
- US infant mortality rose after Supreme Court ended right to abortionBMJ October 23, 2024, 387 q2337; DOI: https://doi.org/10.1136/bmj.q2337
- Leading mesh removal surgeon is suspended for dishonesty and consent irregularitiesBMJ October 23, 2024, 387 q2332; DOI: https://doi.org/10.1136/bmj.q2332
Cited by...
- Postpartum hormonal contraceptive use in Denmark during 1997-2021
- Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study
- Sex and gender in pulmonary arterial hypertension
- Womens health in The BMJ: a data science history
- Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
- FSRH Guideline (January 2019, amended October 2023) Combined Hormonal Contraception
- How I treat heavy menstrual bleeding associated with anticoagulants
- Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes
- Heavy menstrual bleeding: work-up and management
- Low-dose second-generation oral contraceptives are associated with the lowest increased risk of cardiovascular adverse effects
- Testosterone treatment and risk of venous thromboembolism: population based case-control study
- The vascular risks associated with combined oral contraceptives
- Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study
- Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
- Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study
- Defining venous thromboembolism and measuring its incidence using Swedish health registries: a nationwide pregnancy cohort study
- Contraceptive and hormonal treatment options for women with history of venous thromboembolism
- Combined oral contraceptives and risk of venous thromboembolism: there is higher risk in new generations compared to second generations, but paradoxically not in norgestimate-containing-pills
- Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
- Fresh evidence confirms links between newer contraceptive pills and higher risk of venous thromboembolism
- Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study
- MECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism
- The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
- Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke
- Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy
- Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case-control studies using the QResearch and the CPRD databases
- Venous Thromboembolic Disease
- Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis
- Combined hormonal contraceptives and the risk of venous and arterial thromboembolism and cardiovascular death: misuse of automated databases
- Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
- Comorbidity in patients with branch retinal vein occlusion: case-control study
- Risks of venous thromboembolism with various hormonal contraceptives
- Contraception in Patients With Heart Failure
- Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis
- Risk of venous thromboembolism in oral contraceptive users varies according to progestin type
- Another flawed database analysis of VTE risk and hormonal contraceptives
- Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
- DTB Select: 1 | January 2012
- VTE Risk as a Guiding Factor in Oral Contraceptive Selection
- The progestogen content of combined oral contraceptives and venous thromboembolic risk